Intellia Therapeutics Inc (NASDAQ:NTLA)
| 60.57 Delayed Data As of Jul 06 |  -2.67 / -4.23%Today’s Change | 37.08 Today|||52-Week Range 180.59 | -48.77% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $4.1B |
Company Description
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
Contact Information
Intellia Therapeutics, Inc. 40 Erie Street Cambridge Massachusetts 02139 |
Employees
Shareholders
| Mutual fund holders | 54.81% |
| Other institutional | 27.86% |
| Individual stakeholders | 22.23% |
Top Executives
| John M. Leonard | President, Chief Executive Officer & Director |
| Glenn Goddard | Treasurer, Chief Financial & Accounting Officer |
| Laura Sepp-Lorenzino | Chief Scientific Officer & Executive VP |
| David Lebwohl | Chief Medical Officer & Executive Vice President |
| Eliana Clark | Chief Technology Officer & Executive VP |
